Andrew Heaton Appointed Cure JM Chief Scientific Officer

2017 Great Nonprofits Top-Rated Badge

ENCINITAS, CA (September 4, 2018)  –  The Cure JM Foundation has appointed Dr. Andrew Heaton as its first Chief Scientific Officer.

Dr. Heaton brings a 30-year career in pharmaceutical discovery, development, and translational studies, and most recently served as the CEO and President of Heaton-Brown Life Sciences and Novogen North America. Dr. Heaton, ushered several oncology compounds from the laboratory through Phase I, II and III clinical trials.

James Minow, Executive Director of Cure JM said: “Andrew has exceptional experience and a strong track record of innovation in the fields of biotech, drug development and business development. His dedication to finding treatments to rare and life-threatening diseases and compassion for patients and families make him the ideal choice to lead our research program to the next level of achievement.”

The CSO will serve as Cure JM’s science and research leader, proactively driving the growth and effectiveness of Cure JM's grants and clinical research program. In addition, the CSO will provide strategic oversight, guidance, and leadership to the Cure JM Research Priorities. Dr. Heaton will serve as key staff to Cure JM's Research Committee and Medical Advisory Board.

Dr. Heaton received his Bachelor of Science degree from the University of Tasmania, his doctorate from James Cook University of North Queensland, his MBA from Melbourne Business School, and completed a sabbatical at Imperial College, London.

Dr. Heaton is the senior author on over 100, globally granted-patents, covering a wide range of molecular architectures and diseases and has published multiple papers in peer-reviewed scientific journals.

On joining the Cure JM Foundation Dr. Heaton said “It is an honor and privilege to work with an outstanding forward-thinking foundation. Together we have a shared passion for combating rare diseases. I look forward to working with MAB and the Foundation’s Research Committee in translating the research that has been completed and is underway into directed patient-based outcomes.”

About Juvenile Myositis

Juvenile Myositis is a group of rare and life-threatening autoimmune diseases.  Each year, 2 to 4 children per million are diagnosed. JM can cause muscle pain, weakness, fatigue and can attack nearly all systems of the body, often causing a wide range of life-long medical complications.

About Cure JM

Cure JM Foundation is a 501(c)(3) nonprofit organization with the mission to find a cure for Juvenile Myositis and improve the lives of families affected by JM. Learn more at or by contacting .